The Good-The Bad and The Ugly Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Good-The Bad and The Ugly

MAGS 65.96

-0.7%

Dec 31 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Tim Luke who started this subject	10/6/2001 4:16:59 AM
From: Tim Luke	of 8686

Cambridge, UK – 20 September 2000 – Cambridge, UK – 20 September 2000 – Peptide Therapeutics Group plc ("Peptide") (LSE:PTE) announces today that its US subsidiary, OraVax, has been awarded a contract from the U.S. Centers for Disease Control and Prevention ("CDC") to develop and manufacture a new smallpox vaccine. The contract is for a defined period of 20 years. The total amount of the contract is estimated at $343 million. The vaccine will be used to create a US national stockpile for the purpose of countering the threat of bioterrorism. The new smallpox vaccine will be based on the same vaccinia virus strain that was licensed in the U.S. and used for routine immunization against smallpox prior to the global eradication of smallpox in the 1970s. OraVax will be responsible for production in large-scale cell cultures, using modern methods for the manufacture of live-viral vaccines. It will also be responsible for full pre-clinical and clinical testing of the vaccine, which will be licensed by the US FDA for prevention of infection in adults and children. The contract calls for the initial production of a 40 million-dose stockpile. The first deliveries of licensed vaccine to the stockpile are anticipated in mid-2004. The contract also requires sustained production through the life of the contract to both replace out-dated doses and to be able to respond to increased demand on need. OraVax will also supply complete immunization kits for use of the vaccine including the bifurcated needles necessary for vaccine administration.. The CDC plans to hold the new vaccine in reserve, to only be used for the control of smallpox in the event of a confirmed case of smallpox infection. The vaccine may however be used in laboratory workers directly handling vaccinia or related poxviruses. OraVax will have the exclusive commercial rights to the smallpox vaccine developed under the CDC contract. This includes the right to market the vaccine to other US Federal, State, and local agencies as well as commercial and foreign entities. Lance Gordon, Peptide’s Director, North America, said: "This is a major contract which confirms Peptide’s leadership in the development of live virus vaccines. It is a clear endorsement of our technology by no less than the US government and has the potential to earn very substantial revenues for Peptide’s shareholders." OraVax name changed to Acambis (ACAM) peptide.co.uk

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next